Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in Primary Mediastinal B-Cell Lymphoma

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Follicular Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Follicular Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in Follicular Lymphoma

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase II for Diffuse Large B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - CD19+22 CAR-T in Diffuse Large B-Cell Lymphoma

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Marginal Zone B-cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Marginal Zone B-cell Lymphoma....

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Refractory Chronic Lymphocytic Leukemia...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Burkitt Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Burkitt Lymphoma. According to...

Data Insights

CD19+22 CAR-T by Hebei Senlang Biotechnology for Mantle Cell Lymphoma: Likelihood of Approval

CD19+22 CAR-T is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Mantle Cell Lymphoma. According...